24.07
+0.92%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Flexion Therapeutics
Its shares trade under the ticker FLXN. It has been listed since 12 February 2014. In the fiscal year to 31 December 2020, it reported revenue of $85.5m and a net loss of $113.7m. At that date it held total assets of $251.9m and shareholders' equity of −$16.7m.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. The company is headquartered in Burlington, Massachusetts. The company went IPO on 2014-02-12. The firm is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The firm's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The firm is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The firm has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The firm's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The firm is engaged in conducting a Phase IIb clinical trial of Zilretta.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Feb 2014
- Employees
- 257
- Website
- flexiontherapeutics.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Flexion Therapeutics Inc has a strong portfolio of innovative drugs that address unmet needs in the field of pain management.
- The company has a dedicated and experienced research and development team, which allows for the continuous development of new drugs and technologies.
- Flexion Therapeutics Inc has established partnerships and collaborations with key industry players, enhancing its access to resources and expertise.
Weaknesses
- The company heavily relies on a limited number of revenue-generating products, making it vulnerable to potential fluctuations in market demand.
- Flexion Therapeutics Inc has a relatively small market share compared to its competitors, limiting its ability to influence pricing and market dynamics.
- There may be regulatory hurdles and challenges in gaining approval for new drugs, which can lead to delays and increased costs.
Opportunities
- The growing global demand for pain management solutions presents a significant opportunity for Flexion Therapeutics Inc to expand its market presence.
- Technological advancements in drug delivery systems provide an opportunity for the company to develop more convenient and effective treatments, enhancing patient outcomes.
- Strategic partnerships with healthcare providers and institutions can help drive adoption of Flexion Therapeutics Inc's products and establish a strong foothold in the market.
Threats
- Intense competition in the pain management market poses a threat to Flexion Therapeutics Inc's market share and pricing power.
- Changes in regulations and policies related to healthcare and drug pricing can impact the company's profitability and access to markets.
- The potential for adverse side effects or negative publicity related to the use of Flexion Therapeutics Inc's products can damage its reputation and erode customer trust.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.